#ASH18: BeiGene works to bust through the check­point crowd with a piv­otal read­out that proves its PD-1 is bet­ter than the rest

With 2 pi­o­neer­ing PD-1s lord­ing it over the 6 ap­proved check­points in its class, what dif­fer­ence can 1 more make?

The ex­ec­u­tive team at BeiGene is glad you asked.

On Mon­day, the Chi­nese biotech post­ed some re­mark­able re­sults for their piv­otal study aimed at gain­ing a quick OK in Chi­na for their PD-1 tislelizum­ab in treat­ment-re­sis­tant clas­si­cal Hodgkin’s lym­phoma. And they’re tak­ing their best shot at mak­ing a case in San Diego that this one could be sig­nif­i­cant­ly bet­ter than its many ri­vals.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.